Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 8/20 | 0.45 |
| ▸ | MMP9 | P14780 | 7/20 | 0.45 |
| ▸ | APP | P05067 | 5/20 | 0.41 |
| ▸ | MMP13 | P45452 | 12/20 | 0.41 |
| ▸ | MMP3 | P08254 | 6/20 | 0.41 |
| ▸ | MMP8 | P22894 | 3/20 | 0.41 |
| ▸ | MMP1 | P03956 | 7/20 | 0.37 |
| ▸ | MMP14 | P50281 | 3/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | GLA | P06280 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | MMP7 | P09237 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7058199 | 0.90 | MMP2 (0.45) | MMP2MMP9APPMMP13MMP3 | |
| SCHEMBL959465 | 0.83 | APP (0.61) | MMP2MMP9APPMMP13MMP3 | |
| SCHEMBL7056446 | 0.78 | CA12 (0.41) | MMP2MMP9APPMMP13MMP3 | |
| SCHEMBL7217754 | 0.77 | MMP2 (0.39) | MMP2MMP9APPMMP13MMP3 | |
| SCHEMBL3249960 | 0.77 | MMP13 (0.47) | MMP2MMP9MMP13MMP3MMP1 | |
| SCHEMBL3255095 | 0.76 | MMP13 (0.46) | MMP2MMP9APPMMP13MMP3 | |
| SCHEMBL14569171 | 0.76 | MMP2 (0.46) | MMP2MMP9APPMMP13MMP3 | |
| SCHEMBL7055457 | 0.75 | MAPT (0.46) | MMP2MMP9APPMMP13MMP3 | |
| SCHEMBL3254332 | 0.75 | MMP2 (0.42) | MMP2MMP9MMP13MMP1NPC1 | |
| SCHEMBL7549393 | 0.75 | MMP2 (0.42) | MMP2MMP9MMP13MMP1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1373262-B1 | AZACYCLOALKYL SUBSTITUTED ACETIC ACID DERIVATIVES FOR USE AS MMP INHIBITORS | NOVARTIS AG (CH) | 2010-05-12 | — | — | EP | disclosed |
| US-20070060569-A1 | Azacycloalkyl substituted acetic acid derivatives for use as MMP inhibitors | NOVARTIS AG (CH) | 2007-03-15 | — | — | US | disclosed |
| US-20040235896-A1 | Certain azacycloalkyl substituted acetic acid derivatives | FUJIMOTO ROGER AKI (US) | 2004-11-25 | — | — | US | disclosed |
| EP-1373262-A2 | AZACYCLOALKYL SUBSTITUTED ACETIC ACID DERIVATIVES FOR USE AS MMP INHIBITORS | Novartis AG (CH) | 2004-01-02 | — | — | EP | disclosed |
| WO-2002072577-A2 | AZACYCLOALKYL SUBSTITUTED ACETIC ACID DERIVATIVES FOR USE AS MMP INHIBITORS. | NOVARTIS AG (CH) | 2002-09-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070060569-A1 | Azacycloalkyl substituted acetic acid derivatives for use as MMP inhibitors | MMP9, MMP1, MMP13 | MMP2 4/4885MMP9 1/4885APP 2059/4885 |
| US-20040235896-A1 | Certain azacycloalkyl substituted acetic acid derivatives | MMP1, MMP9, MMP13 | MMP2 4/4885MMP9 2/4885APP 2276/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.